

REMARKABLE SCIENCE CHANGES EVERYTHING™

REVANCE AESTHETICS

Revance is focusing on the largest demand within the facial aesthetics category, glabellar (frown) lines.



Deep facial muscles that form frown lines are approved for treatment by current injectable botulinum toxins and are estimated to represent a nearly \$1 billion global market opportunity. These marketed neurotoxins have shown duration of effect of approximately 3-4 months. In a Phase 2 trial, DaxibotulinumtoxinA for Injection (RT002) achieved a 6-month duration of effect. The Company has initiated a Phase 3 clinical program using RT002 injectable for the treatment of frown lines and plans to release topline results in fourth quarter of 2017.

REVANCE THERAPEUTICS

The therapeutic portion of the global neurotoxin market was estimated to be \$1.8 billion in 2015, larger and faster-growing than aesthetics. Revance plans to build a significant therapeutics portfolio, initially addressing cervical dystonia and plantar fasciitis.



Cervical dystonia is a very painful and debilitating neurologic disorder affecting the neck and shoulder muscles. Treatment for cervical dystonia involves regular neurological intervention. The most commonly prescribed treatment for cervical dystonia is botulinum toxin type A, which can reduce the signs and symptoms of the affliction. In December

2016, the company released positive interim results from its Phase 2 dose-escalating trial using RT002 injectable for the treatment of cervical dystonia and plans to release full results in the first half of 2017.

Plantar fasciitis, the most common cause of heel pain, is triggered by inflammation of the connective tissue in the arch of the foot. The company has initiated a Phase 2 trial using RT002 injectable to reduce the signs and symptoms of plantar fasciitis. Results are expected in the second half of 2017.

RT001 TOPICAL

Revance is pursuing indications for its DaxibotulinumtoxinA Topical Gel (RT001) where topical administration of botulinum toxin provides a meaningful advantage over injection. It is designed to provide treatment with no needles, no downtime, no bruising and no pain. RT001 topical is in preclinical development as a potential treatment for a number of aesthetic and therapeutic uses.

2016 FINANCIAL OUTLOOK (AS OF JANUARY 5, 2017)

The company had unaudited cash and investments of \$185 million at year end 2016. Cash burn for 2017 is expected to be in the range of \$102-\$112 million. The company expects its current cash and investments to fund operations into the third quarter of 2018.

SELL-SIDE COVERAGE

FIRM	ANALYST
Aegis Capital Corp	Difei Yang
Cowen and Company	Ken Cacciatore
Guggenheim Securities, LLC	Louise Chen
Piper Jaffray & Company	David Amsellem
SunTrust Robinson Humphrey, Inc.	John T. Boris
William Blair	Tim Lugo

BOARD OF DIRECTORS

Angus C. Russell
Chairman of the Board

Dan Browne
Co-Founder, President & CEO

Robert Byrnes
Experienced Medical Device &
Biotechnology Executive

Ronald Eastman
Essex Woodlands Health Ventures

Phyllis Gardner, M.D.
Professor of Medicine,
Stanford University

Julian S. Gangolli
GW Pharmaceuticals Inc.

Mark A. Prygocki, Sr.
Valleymark Strategic Advisors

Philip Vickers, Ph.D.
Shire plc

MANAGEMENT TEAM

Dan Browne
Co-Founder, President & CEO

Lauren Silvernail
CFO & Chief Business Officer

Abhay Joshi, Ph.D.
Chief Operating Officer

Roman Rubio, M.D.
SVP, Clinical Development

Mukul Agarwal
VP, Business Development

Azita Nejad
VP, Quality and Validations

FORWARD-LOOKING STATEMENTS

This Investor Fact Sheet contains forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties are risks described in the "Risk Factors" section of the Form 10-Q filed November 4, 2016. These forward-looking statements speak only as of the date hereof. Revance disclaims any obligation to update these forward-looking statements.

"Revance Therapeutics", TransMTS®, "Remarkable Science Changes Everything", and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

© 2017 Revance Therapeutics, Inc.
All rights reserved.